Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Novartis AG

Is Aducanumab In Alzheimer’s A Candidate For Medicare ‘Coverage With Evidence Development’?

Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.

Reimbursement Medicare

Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors

Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round. 

Financing Innovation

Piqray: German Withdrawal, European Reimbursement Deals & Broader Indication Plans

Novartis has failed to reach a reimbursement agreement to keep its first-in-class advanced breast cancer drug on the German market, but it is pressing on with plans to expand market access for the product across Europe. It is also working on securing regulatory approval to use Piqray in a broader patient population that would carve out a more meaningful place in the relevant treatment pathway.

Germany Health Technology Assessment

Amryt Predicts $1bn Revenues After Chiasma Acquisition

The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.

M & A Rare Diseases
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Admune Therapeutics
    • Amblyotech, Inc.
    • Advanced Accelerator Applications SA (AAAP) (BioSynthema, Inc.)
    • Aspen Japan K.K.
    • Biocine
    • CELLforCURE SASU
    • Chiron Corporation
    • CIBA-GEIGY
    • Corthera Inc.
    • CoStim Pharmaceuticals Inc.
    • ESBATech AG
    • Fougera Pharmaceuticals, Inc.
    • Hexal AG
    • Lek Pharmaceuticals, Inc.
    • Matrix Pharmaceuticals
    • NeuTec Pharma
    • Novartis Groupe France S.A.
    • Novartis Pharmaceuticals
    • Novartis Oncology
    • Novogyne Pharmaceuticals (joint venture between Noven and Novartis)
    • PowerVision, Inc.
    • Protez Pharmaceuticals
    • Sandoz Pharmaceuticals (Ever Neuro Pharma GmbH
    • Ebewe Pharma)
    • Selexys Pharmaceuticals Corporation
    • Speedel Holding
    • Spinifex Pharmaceuticals Pty. Ltd.
    • Transcend Medical, Inc.
    • Encore Vision, Inc.
    • Ziarco Group Limited
    • AveXis, Inc.
    • BioLife Cell Bank, Inc.
    • Endocyte, Inc.
    • IFM Tre
    • Zyma SA
    • Annovation Biopharma, Inc.
    • Boxford Subsidiary
    • Curacyte Discovery GmbH
    • Incline Therapeutics, Inc.
    • ProFibrix B.V.
    • Rempex Pharmaceuticals, Inc.
    • Targanta Therapeutics Corporation
    • Tenaxis Medical
    • The Medicines Company
    • Novartis Gene Therapies
UsernamePublicRestriction

Register